EDAP TMS (NASDAQ: EDAP) is one of 82 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its rivals? We will compare EDAP TMS to similar businesses based on the strength of its earnings, profitability, valuation, analyst recommendations, institutional ownership, risk and dividends.


This table compares EDAP TMS and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
EDAP TMS -0.27% 10.31% 5.56%
EDAP TMS Competitors -370.66% -34.79% -11.97%

Earnings & Valuation

This table compares EDAP TMS and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
EDAP TMS $44.00 million $270,377.00 -309.69
EDAP TMS Competitors $2.06 billion $438.96 million -67.68

EDAP TMS’s rivals have higher revenue and earnings than EDAP TMS. EDAP TMS is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings for EDAP TMS and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EDAP TMS 0 0 1 0 3.00
EDAP TMS Competitors 259 1823 3281 105 2.59

EDAP TMS presently has a consensus target price of $6.50, indicating a potential upside of 109.68%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 7.70%. Given EDAP TMS’s stronger consensus rating and higher possible upside, equities analysts clearly believe EDAP TMS is more favorable than its rivals.

Volatility & Risk

EDAP TMS has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500. Comparatively, EDAP TMS’s rivals have a beta of 0.89, meaning that their average share price is 11% less volatile than the S&P 500.

Institutional & Insider Ownership

9.4% of EDAP TMS shares are owned by institutional investors. Comparatively, 51.0% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 18.6% of shares of all “Advanced Medical Equipment & Technology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.


EDAP TMS beats its rivals on 8 of the 13 factors compared.

EDAP TMS Company Profile

EDAP TMS S.A. (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors. The Company also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL) and distributes other types of urology devices in certain countries. The HIFU division is engaged in the development, manufacturing and marketing of medical devices based on HIFU technology for the invasive treatment of urological and other clinical indications. The UDS division is engaged in the development, marketing, manufacturing and servicing of medical devices for the invasive diagnosis or treatment of urological disorders, urinary stones, and other clinical indications.

Receive News & Ratings for EDAP TMS S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EDAP TMS S.A. and related companies with MarketBeat.com's FREE daily email newsletter.